Prevalence of hepatitis B in children in a high risk New Zealand community, and control using recombinant DNA vaccine.
Two hundred and sixty-six children aged 3-10 years were tested for hepatitis B virus (HBV) serologic markers. Thirty-eight were positive, including seven who were positive for hepatitis B surface antigen (HBsAg). Two hundred and fifteen healthy children were randomised to receive either 3 x 5 micrograms doses or 3 x 10 micrograms doses of Smith Kline Biologicals Engerix B recombinant DNA (rDNA) hepatitis B vaccine into the deltoid muscle at 0, 1 and 6 months. They were tested for seroconversion and levels of antibody to hepatitis B surface antigen (anti-HBs) one month after dose 3. Ninety-nine percent of children in each group seroconverted for anti-HBs. Geometric mean titres (GMT) or anti-HBs in IU/L were higher with 10 micrograms doses. Nevertheless, 3 x 5 micrograms is the appropriate regimen for protecting children in this age group, as long as cost of vaccine remains a major factor in immunisation programmes.